Indacaterol/glycopyrronium bromide

Indacaterol/glycopyrronium bromide
Combination of
Indacaterol	Ultra-long-acting beta-adrenoceptor agonist
Glycopyrronium bromide	Muscarinic anticholinergic
Clinical data
Trade names	Ultibro Breezhaler, Utibron Neohaler, Xoterna Breezhaler
Pregnancy; category	AU: B3;
Routes of; administration	Inhalation only
ATC code	R03AL04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	444313-53-5 ;
PubChem CID	11564052;
KEGG	D10505;
CompTox Dashboard (EPA)	DTXSID60155126 ;

Indacaterol/glycopyrronium bromide, sold under the brand name Ultibro Breezhaler among others, is a fixed-dose combination medication for inhalation consisting of the following two active ingredients:

Indacaterol maleate—an ultra-long-acting beta-adrenoceptor agonist (ultra-LABA);
Glycopyrronium bromide (glycopyrrolate)—a muscarinic anticholinergic.

Indacaterol maleate/glycopyrronium bromide is used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

The drug is marketed by Novartis under the trade names Ultibro Breezhaler and Utibron Neohaler in Europe and the United States, respectively. In 2016, Novartis licensed its U.S. commercial rights for Seebri Neohaler and Utibron Neohaler to Sunovion Pharmaceuticals.